MX2009004910A - Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. - Google Patents
Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo.Info
- Publication number
- MX2009004910A MX2009004910A MX2009004910A MX2009004910A MX2009004910A MX 2009004910 A MX2009004910 A MX 2009004910A MX 2009004910 A MX2009004910 A MX 2009004910A MX 2009004910 A MX2009004910 A MX 2009004910A MX 2009004910 A MX2009004910 A MX 2009004910A
- Authority
- MX
- Mexico
- Prior art keywords
- compounds
- isoquinolin
- pyrido
- hexahydro
- dimethoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US86494406P | 2006-11-08 | 2006-11-08 | |
| PCT/US2007/084176 WO2008058261A1 (en) | 2006-11-08 | 2007-11-08 | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a] isoquinolin-2-ol compounds and methods relating thereto |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2009004910A true MX2009004910A (es) | 2009-07-24 |
Family
ID=39110526
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2009004910A MX2009004910A (es) | 2006-11-08 | 2007-11-08 | Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US8039627B2 (enExample) |
| EP (1) | EP2081929B1 (enExample) |
| JP (1) | JP5290185B2 (enExample) |
| KR (1) | KR101500766B1 (enExample) |
| CN (1) | CN101553487B (enExample) |
| AU (1) | AU2007317242B2 (enExample) |
| BR (1) | BRPI0718247B1 (enExample) |
| CA (1) | CA2668689C (enExample) |
| DK (1) | DK2081929T3 (enExample) |
| EA (1) | EA018378B1 (enExample) |
| ES (1) | ES2402220T3 (enExample) |
| IL (1) | IL198250A0 (enExample) |
| MX (1) | MX2009004910A (enExample) |
| PL (1) | PL2081929T3 (enExample) |
| PT (1) | PT2081929E (enExample) |
| WO (1) | WO2008058261A1 (enExample) |
Families Citing this family (73)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
| CA2972242A1 (en) | 2008-09-18 | 2010-04-22 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| EP3351247A1 (en) * | 2010-06-01 | 2018-07-25 | Auspex Pharmaceutical, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2012000308A1 (zh) * | 2010-06-29 | 2012-01-05 | 中国药科大学 | 丁苯那嗪的拆分方法 |
| US8351329B2 (en) * | 2010-09-14 | 2013-01-08 | Cisco Technology, Inc. | Universal load-balancing tunnel encapsulation |
| CN102285984B (zh) * | 2010-11-25 | 2012-10-10 | 江苏威凯尔医药科技有限公司 | (2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法 |
| WO2012081031A1 (en) | 2010-12-15 | 2012-06-21 | Enaltec Labs Pvt. Ltd. | Process for preparing tetrabenazine |
| EP4345100A3 (en) | 2012-09-18 | 2024-04-10 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| US9550780B2 (en) | 2012-09-18 | 2017-01-24 | Auspex Pharmaceuticals, Inc. | Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| JP2016506957A (ja) * | 2013-01-31 | 2016-03-07 | オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． | Ｖｍａｔ２のベンゾキノロン阻害剤 |
| WO2015048370A1 (en) * | 2013-09-27 | 2015-04-02 | Auspex Pharmaceuticals, Inc. | Benzoquinolone inhibitors of vmat2 |
| WO2015084622A1 (en) * | 2013-12-03 | 2015-06-11 | Auspex Pharmaceuticals, Inc. | Methods of manufacturing benzoquinoline compounds |
| EP3398602A1 (en) * | 2014-01-27 | 2018-11-07 | Auspex Pharmaceuticals, Inc. | Benzoquinoline inhibitors of vesicular monoamine transporter 2 |
| KR20160117596A (ko) | 2014-02-07 | 2016-10-10 | 오스펙스 파마슈티칼스, 인코포레이티드 | 신규 제약 제제 |
| CN106061506A (zh) * | 2014-02-07 | 2016-10-26 | 纽罗克里生物科学有限公司 | 包含抗精神病药物和vmat2抑制剂的药物组合物及其用途 |
| EP3105218B1 (en) | 2014-02-13 | 2019-09-25 | Incyte Corporation | Cyclopropylamines as lsd1 inhibitors |
| NZ725826A (en) * | 2014-05-06 | 2023-05-26 | Neurocrine Biosciences Inc | Vmat2 inhibitors for the treatment of hyperkinetic movement disorders |
| US9714246B2 (en) * | 2015-02-06 | 2017-07-25 | Neurocrine Biosciences, Inc. | [9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto |
| AU2016229949B2 (en) | 2015-03-06 | 2021-04-08 | Auspex Pharmaceuticals Llc | Methods for the treatment of abnormal involuntary movement disorders |
| EP3277689B1 (en) | 2015-04-03 | 2019-09-04 | Incyte Corporation | Heterocyclic compounds as lsd1 inhibitors |
| KR20240125709A (ko) | 2015-06-23 | 2024-08-19 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 신경계 질환 또는 장애를 치료하기 위한 vmat2 억제제 |
| MY189367A (en) | 2015-08-12 | 2022-02-08 | Incyte Corp | Salts of an lsd1 inhibitor |
| MX383906B (es) | 2015-10-09 | 2025-03-14 | Teva Pharmaceuticals Int Gmbh | Combinación de levodopa deuterado con carbidopa y opicapona para el tratamiento del mal de parkinson |
| RS61645B1 (sr) * | 2015-10-30 | 2021-04-29 | Neurocrine Biosciences Inc | Valbenazin ditozilat i njihovi polimorfi |
| JP6869988B2 (ja) * | 2015-12-23 | 2021-05-12 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | （Ｓ）−（２Ｒ，３Ｒ，１１ｂＲ）−３−イソブチル−９，１０−ジメトキシ−２，３，４，６，７，１１ｂ−ヘキサヒドロ−１Ｈ−ピリド［２，１−ａ］イソキノリン−２−イル２−アミノ−３−メチルブタノエートジ（４−メチルベンゼンスルホネート）の調製のための合成方法 |
| WO2017182916A1 (en) * | 2016-04-22 | 2017-10-26 | Lupin Limited | Novel process for preparation of tetrabenazine and deutetrabenazine |
| US10442800B2 (en) * | 2016-06-29 | 2019-10-15 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal forms of NBI-98854, preparation method and use thereof |
| WO2018067945A1 (en) | 2016-10-06 | 2018-04-12 | Assia Chemical Industries Ltd. | Solid state forms of valbenazine |
| WO2018102673A1 (en) | 2016-12-02 | 2018-06-07 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating schizophrenia or schizoaffective disorder |
| US10703750B2 (en) | 2017-01-10 | 2020-07-07 | Sandoz Ag | Crystalline valbenazine free base |
| CA3051830A1 (en) | 2017-01-27 | 2018-08-02 | Neurocrine Bioscienes, Inc. | Methods for the administration of certain vmat2 inhibitors |
| EP3585787A1 (en) | 2017-02-27 | 2020-01-01 | Sandoz AG | Crystalline forms of valbenazine salts |
| WO2018164996A1 (en) | 2017-03-06 | 2018-09-13 | Neurocrine Biosciences, Inc. | Dosing regimen for valbenazine |
| PE20191819A1 (es) | 2017-03-15 | 2019-12-27 | Auspex Pharmaceuticals Inc | Analogos de deutetrabenazina, su preparacion y uso |
| GB201705306D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| AU2018241940B2 (en) * | 2017-04-01 | 2023-09-28 | Adeptio Pharmaceuticals Limited | Dihydrotetrabenazine for use in the treatment a movement disorder |
| GB201705304D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705302D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705305D0 (en) | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| GB201705303D0 (en) * | 2017-04-01 | 2017-05-17 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compositions |
| JOP20190239A1 (ar) * | 2017-04-19 | 2019-10-09 | Neurocrine Biosciences Inc | مركبات مثبطة لـ vmat2 وتركيبات منها |
| WO2018200605A1 (en) | 2017-04-26 | 2018-11-01 | Neurocrine Biosciences, Inc. | Use of valbenazine for treating levodopa-induced dyskinesia |
| CA3076000A1 (en) | 2017-09-21 | 2019-03-28 | Neurocrine Biosciences, Inc. | High dosage valbenazine formulation and compositions, methods, and kits related thereto |
| KR20250070134A (ko) | 2017-10-10 | 2025-05-20 | 뉴로크린 바이오사이언시즈 인코퍼레이티드 | 특정 vmat2 억제제의 투여 방법 |
| JP2021502959A (ja) | 2017-10-10 | 2021-02-04 | ニューロクライン バイオサイエンシーズ，インコーポレイテッド | 特定のｖｍａｔ２インヒビターを投与するための方法 |
| SG11202004165UA (en) * | 2017-11-08 | 2020-06-29 | Yuhua Li | Esters of dihydrotetrabenazine |
| AU2018371771B2 (en) | 2017-11-22 | 2024-06-20 | Assia Chemical Industries Ltd | Solid state form of Valbenazine |
| JP7212958B2 (ja) | 2017-12-26 | 2023-01-26 | ▲蘇▼州科睿思制▲葯▼有限公司 | バルベナジントシル酸塩の結晶形及びその製造方法並びに用途 |
| CN110092785A (zh) * | 2018-01-31 | 2019-08-06 | 广东东阳光药业有限公司 | 一种丁苯那嗪的动态拆分方法 |
| GB201808464D0 (en) | 2018-05-23 | 2018-07-11 | Adeptio Pharmaceuticals Ltd | Pharmaceutical compounds for use in treating huntington's disease |
| AU2019287524A1 (en) * | 2018-06-14 | 2020-12-24 | Neurocrine Biosciences, Inc. | VMAT2 inhibitor compounds, compositions, and methods relating thereto |
| MA53239A (fr) | 2018-08-15 | 2022-05-04 | Neurocrine Biosciences Inc | Procédés d'administration de certains inhibiteurs de vmat2 |
| US10968200B2 (en) | 2018-08-31 | 2021-04-06 | Incyte Corporation | Salts of an LSD1 inhibitor and processes for preparing the same |
| EP3860599B1 (en) | 2018-10-04 | 2024-05-15 | Adeptio Pharmaceuticals Limited | (+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders |
| CA3065236A1 (en) | 2018-12-27 | 2020-06-27 | Apotex Inc. | Novel crystalline form of valbenazine dibesylate |
| WO2020213014A1 (en) | 2019-04-19 | 2020-10-22 | Mylan Laboratories Limited | An improved process for the preparation of valbenazine and its salts |
| US10689380B1 (en) | 2019-07-30 | 2020-06-23 | Farmhispania S.A. | Crystalline forms of valbenazine ditosylate |
| US12565495B2 (en) * | 2019-08-12 | 2026-03-03 | Luye Innomind Pharma Shijiazhuang Co., Ltd. | VMAT2 inhibitor and preparation method therefor and application thereof |
| US10940141B1 (en) | 2019-08-23 | 2021-03-09 | Neurocrine Biosciences, Inc. | Methods for the administration of certain VMAT2 inhibitors |
| CA3150961A1 (en) | 2019-09-13 | 2021-03-18 | John Tucker | Processes for the synthesis of valbenazine |
| CN110698397A (zh) * | 2019-10-28 | 2020-01-17 | 南京红杉生物科技有限公司 | 丁苯那嗪中间体及其合成方法、应用和合成用中间产物 |
| AU2022241988A1 (en) | 2021-03-22 | 2023-10-12 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
| EP4330255A1 (en) | 2021-04-26 | 2024-03-06 | Neurocrine Biosciences, Inc. | Processes for the synthesis of valbenazine |
| BR112023026160A2 (pt) | 2021-06-30 | 2024-03-05 | Neurocrine Biosciences Inc | Valbenazina para uso no tratamento de discinesia devido à paralisia cerebral |
| CA3220946A1 (en) | 2021-06-30 | 2023-01-05 | Angel S. Angelov | Valbenazine for use in the add-on treatment of schizophrenia |
| EP4489754A1 (en) | 2022-03-07 | 2025-01-15 | Neurocrine Biosciences, Inc. | Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease |
| IL319670A (en) | 2022-09-21 | 2025-05-01 | Neurocrine Biosciences Inc | VMAT2 inhibitors based on hexahydro-2H-pyridyl-1,2-[A]isoquinoline and methods of use |
| TW202521119A (zh) | 2023-08-17 | 2025-06-01 | 美商紐羅克里生物科學有限公司 | 用於投與特定vmat2抑制劑之方法 |
| WO2025038959A1 (en) | 2023-08-17 | 2025-02-20 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025096823A1 (en) | 2023-11-01 | 2025-05-08 | Neurocrine Biosciences, Inc. | Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine |
| WO2025188830A1 (en) | 2024-03-06 | 2025-09-12 | Neurocrine Biosciences, Inc. | Methods for the administration of certain vmat2 inhibitors |
| WO2025199234A1 (en) | 2024-03-20 | 2025-09-25 | Neurocrine Biosciences, Inc. | Vmat2 inhibitors and methods of use |
| WO2026050236A1 (en) | 2024-08-27 | 2026-03-05 | Neurocrine Biosciences, Inc. | Muscarinic receptor agonist in combination with a vesicular monoamine transporter 2 inhibitor, for use in the treatment of a neurological or psychiatric disorder |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3209005A (en) * | 1965-09-28 | Hexahydro-llbh-benzo[a] quinolizines and processes therefor | ||
| US2843591A (en) * | 1958-07-15 | Method for preparing same | ||
| US2852518A (en) * | 1957-05-23 | 1958-09-16 | Parke Davis & Co | Di-substituted quinoline compounds |
| WO1991016920A1 (en) | 1990-05-07 | 1991-11-14 | Vical, Inc. | Lipid prodrugs of salicylate and nonsteroidal anti-inflammatory drugs |
| US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
| US7045543B2 (en) * | 2001-11-05 | 2006-05-16 | Enzrel Inc. | Covalent conjugates of biologically-active compounds with amino acids and amino acid derivatives for targeting to physiologically-protected sites |
| GB2410947B (en) | 2004-02-11 | 2008-09-17 | Cambridge Lab Ltd | Pharmaceutical compounds |
| WO2006053067A2 (en) | 2004-11-09 | 2006-05-18 | Prestwick Pharmaceuticals, Inc. | Combination of amantadine and a tetrabenazine compound for treating hyperkinetic disorders |
| EP1907017A4 (en) | 2005-06-29 | 2011-05-04 | Univ Columbia | USE OF DTBZ FOR THE PRESENTATION OF ENDOCRINE PANCREAS AND BETAZELL MASS IN DIABETES TYPE 1 |
| GB0514501D0 (en) | 2005-07-14 | 2005-08-24 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| GB0516168D0 (en) | 2005-08-05 | 2005-09-14 | Cambridge Lab Ireland Ltd | Pharmaceutical compounds |
| NZ566011A (en) | 2005-08-06 | 2011-01-28 | Biovail Lab Internat Barbados Srl | 3, 11b cis dihydrotetrabenazine for the treatment of schizophrenia and other psychoses |
| EP2081929B1 (en) | 2006-11-08 | 2013-01-09 | Neurocrine Biosciences, Inc. | Substituted 3-isobutyl-9, 10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto |
-
2007
- 2007-11-08 EP EP07864160A patent/EP2081929B1/en active Active
- 2007-11-08 BR BRPI0718247-3A patent/BRPI0718247B1/pt active IP Right Grant
- 2007-11-08 ES ES07864160T patent/ES2402220T3/es active Active
- 2007-11-08 AU AU2007317242A patent/AU2007317242B2/en active Active
- 2007-11-08 MX MX2009004910A patent/MX2009004910A/es active IP Right Grant
- 2007-11-08 DK DK07864160.2T patent/DK2081929T3/da active
- 2007-11-08 CN CN2007800395790A patent/CN101553487B/zh active Active
- 2007-11-08 EA EA200970461A patent/EA018378B1/ru unknown
- 2007-11-08 PT PT78641602T patent/PT2081929E/pt unknown
- 2007-11-08 PL PL07864160T patent/PL2081929T3/pl unknown
- 2007-11-08 WO PCT/US2007/084176 patent/WO2008058261A1/en not_active Ceased
- 2007-11-08 US US11/937,445 patent/US8039627B2/en active Active
- 2007-11-08 JP JP2009536493A patent/JP5290185B2/ja active Active
- 2007-11-08 CA CA2668689A patent/CA2668689C/en active Active
- 2007-11-08 KR KR1020097011731A patent/KR101500766B1/ko active Active
-
2009
- 2009-04-21 IL IL198250A patent/IL198250A0/en active IP Right Grant
-
2011
- 2011-09-20 US US13/237,709 patent/US8357697B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US8357697B2 (en) | 2013-01-22 |
| CN101553487A (zh) | 2009-10-07 |
| ES2402220T8 (es) | 2021-12-23 |
| EP2081929B1 (en) | 2013-01-09 |
| CA2668689C (en) | 2015-12-29 |
| JP2010509366A (ja) | 2010-03-25 |
| KR20090079257A (ko) | 2009-07-21 |
| AU2007317242B2 (en) | 2013-08-01 |
| EA200970461A1 (ru) | 2009-12-30 |
| DK2081929T3 (da) | 2013-04-15 |
| ES2402220T3 (es) | 2013-04-29 |
| PL2081929T3 (pl) | 2013-06-28 |
| JP5290185B2 (ja) | 2013-09-18 |
| AU2007317242A1 (en) | 2008-05-15 |
| CA2668689A1 (en) | 2008-05-15 |
| EP2081929A1 (en) | 2009-07-29 |
| WO2008058261A1 (en) | 2008-05-15 |
| KR101500766B9 (ko) | 2024-09-25 |
| US20120077839A1 (en) | 2012-03-29 |
| BRPI0718247B1 (pt) | 2021-09-21 |
| US20080167337A1 (en) | 2008-07-10 |
| CN101553487B (zh) | 2012-06-13 |
| KR101500766B1 (ko) | 2015-03-16 |
| BRPI0718247A2 (pt) | 2014-01-07 |
| EA018378B1 (ru) | 2013-07-30 |
| PT2081929E (pt) | 2013-04-15 |
| US8039627B2 (en) | 2011-10-18 |
| IL198250A0 (en) | 2009-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2009004910A (es) | Compuestos sustituidos de 3-isobutil-9,10-dimetoxi-1,3,4,6,7,11-b- hexahidro-2h-pirido[2,1-a] isoquinolin-2-ol y métodos que se relacionan al mismo. | |
| MX2007004699A (es) | Derivados de indol y bencimidazol. | |
| TW200612958A (en) | Substituted imidazole derivatives | |
| UA94606C2 (ru) | Производные тиоксантина, композиция, которая их содержит, и их применение в терапии | |
| PH12012501711A1 (en) | [5,6] heterocyclic compound | |
| MX375718B (es) | [9,10-dimetoxi-3-(2-metilpropil)-1h,2h,3h,4h,6h,7h,11bh-pirido-[2,1-a]isoquinolin-2-il]metanol y compuestos, composiciones y metodos relacionados con los mismos. | |
| WO2008120725A1 (ja) | 新規ピロリノン誘導体およびそれを含有する医薬組成物 | |
| SE0202463D0 (sv) | Novel compounds | |
| PT1940839E (pt) | Inibidores de piridopirimidinona pi3k alfa | |
| MX2010002266A (es) | Derivados de pirazol sustituidos. | |
| MX2010004493A (es) | Compuestos de tropano. | |
| MX2010006882A (es) | Derivado novedoso de catecol, composición farmaceutica que contiene el mismo, uso del derivado de catecol, y uso de la composición farmaceutica. | |
| MX2007003546A (es) | Derivados de indozolona como inhibidores de 11-beta- hidroxiesteroide-deshidrogenasa. | |
| MX2009005217A (es) | Compuestos heterociclicos que contienen nitrogeno y metodos de uso de los mismos. | |
| WO2008108378A3 (en) | Bicyclic oxomorpholine derivative | |
| MX2013003019A (es) | Compuestos de azabenzotiazol, composiciones y metodos de uso. | |
| TN2009000287A1 (en) | Cyclized derivatives as eg-5inhibitors | |
| TW200606151A (en) | Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions | |
| JOP20190239A1 (ar) | مركبات مثبطة لـ vmat2 وتركيبات منها | |
| UA96947C2 (ru) | Производные циннамоил-пиперазина и их применение как антагонистов par-1 | |
| NO20083708L (no) | 4-Fenyl-tiazol-5-karboksylsyre og 4-fenyl-tiazol-5-karboksylmider som PLK1-inhibitorer | |
| GB0607954D0 (en) | Organic compounds | |
| MX2010001566A (es) | Derivado de aminopirazolamida. | |
| MX2007013624A (es) | Inhibidores de proteina cinasa. | |
| MY136824A (en) | Substituted benzoxazinones and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |